A GLP-1 provider has to clear a higher bar in 2026. The market now rewards transparent pharmacy sourcing, clean pricing, and real physician review more than vague promises about access.
Here are eight that hold up to scrutiny.
1. HealthRX
The standout fact here is the price floor. Compounded semaglutide from $99 a month and tirzepatide from $149 puts HealthRX well below most cash-pay telehealth options, and the pricing is published upfront with no hidden fees buried at checkout. Overnight shipping is free to all 50 states, which matters when you are comparing providers that restrict certain states or charge for expedited delivery.
What earns more confidence than the price alone: the compounding pharmacy is identified by name. Manifest Pharmacy in Greer, South Carolina is a 503A facility operating under USP-797 standards with lot-tracked production and LegitScript certification (cert 50087439). A lot of telehealth platforms list a general pharmacy partner. Naming the specific facility and its certifications is a different level of transparency. A board-certified U.S. physician reviews each assessment within roughly 24 hours, and medication ships overnight after approval.
Worth saying plainly: compounded medications are not FDA-approved products. They are legal, regulated preparations, but they are not the same as the branded drugs in clinical trials. The trial data HealthRX cites, roughly 21% average body weight reduction with tirzepatide at 72 weeks from SURMOUNT-1 and about 15% with semaglutide at 68 weeks from STEP 1, comes from those branded-drug studies, not from HealthRX’s own compounded formulations.
Best for: Cash-pay patients who want verified pharmacy sourcing and the lowest entry price available from a legitimate 503A provider.
2. FormBlends
FormBlends operates a compounded GLP-1 telehealth model with physician oversight and dispensing through an FDA-registered 503A compounding pharmacy. What separates it from most competitors is what it publishes. Per-product testing reports include HPLC purity figures, mass spectrometry identity confirmation, and endotoxin and sterility results with named numbers attached. That is genuinely uncommon in this category.
Pricing runs higher than HealthRX: semaglutide around $299 per vial and tirzepatide around $349. Shipping covers 47 states, not all 50. So if cost-per-month is the deciding factor, FormBlends is not the winner. But if you want to read actual purity data before injecting a compounded peptide, very few providers offer that.
The other differentiator is scope. FormBlends also carries a peptide catalog covering recovery, longevity, and cognitive categories under the same clinician model. Most GLP-1-only telehealth brands simply do not do that.
Best for: Someone who values published lab testing over lowest price, or who wants GLP-1s and a broader peptide protocol from one provider.
3. Mochi Health
Mochi pairs compounded semaglutide at $99 a month and tirzepatide at $199 with board-certified obesity-medicine clinicians, not just general practitioners. The monitoring is more hands-on than most platforms at this price point. If clinical depth matters to you alongside cash pricing, Mochi sits in a better position than many.
4. Ro Body
Ro‘s membership starts at $39 for the first month, then runs $74 to $149 depending on the plan, with medications billed separately. It has a dedicated prior-authorization team for branded medications, which is a real advantage if you have insurance and want to try for covered Wegovy or Zepbound. Not every platform invests in that process.
*A quick honest note: this article reflects publicly available information as of mid-2026. Individual eligibility, state availability, and medication pricing change frequently. Confirm details directly with any provider before signing up.*
5. Hims & Hers
After the March 2026 Novo settlement, Hims & Hers moved away from compounded semaglutide and toward branded medications. Injectable Wegovy runs about $299 a month through the platform, oral semaglutide around $249, and Zepbound approximately $399. With insurance and manufacturer savings cards, some patients reach $0 to $25 monthly costs. The brand recognition is high, but so is the base price for uninsured patients.
6. PlushCare
PlushCare’s membership sits at $19.99 a month with same-day visit availability and insurance acceptance for branded medications. It functions more like a traditional primary care platform that also handles weight management than a dedicated GLP-1 service. That is not a criticism. For patients who want one platform handling multiple health needs, that breadth is the point.
7. Found
Found charges roughly $99 a month for the platform plus medication costs on top. Coaching is built in. The structure suits people who want behavioral support alongside medication rather than medication alone.
8. Henry Meds
Henry Meds uses a cash-pay compounded model with first-month pricing between $179 and $249 and shipping that typically arrives within 24 to 72 hours. Monitoring is lighter than Mochi or Calibrate. Fast access and straightforward pricing are the draws.
How to Compare These Providers
| Provider | Starting Price | Pharmacy Transparency | All 50 States | Insurance Option |
| HealthRX | $99/mo (sema) | Named 503A, lot-tracked, LegitScript | Yes | No |
| FormBlends | ~$299/vial (sema) | Named 503A, published purity testing | 47 states | No |
| Mochi Health | $99/mo (sema) | Not specified publicly | Yes | No |
| Hims & Hers | ~$249-399/mo | Branded meds post-settlement | Yes | Yes |
| Ro Body | $39 first month + meds | Branded + prior-auth team | Yes | Yes |
| PlushCare | $19.99/mo + meds | Branded meds | Yes | Yes |
| Found | ~$99/mo + meds | Not specified publicly | Yes | Partial |
| Henry Meds | $179-249/mo | Not specified publicly | Yes | No |
The providers at the top of this list earn that position on transparency and price specificity, not just name recognition. Compounded GLP-1s remain legal under 503A pharmacy rules, but FDA approval does not apply to them. Anyone prescribing or dispensing these medications should be able to tell you exactly where the product is made and what standards it meets.
Common Questions
Does it matter which compounding pharmacy a telehealth platform uses?
It matters more than most patients realize. A named 503A facility operating under USP-797 standards with lot-tracked production is a different thing from a vague “pharmacy partner.” HealthRX names Manifest Pharmacy specifically and lists a LegitScript certification number. That kind of specificity gives you something concrete to verify before committing.
Is compounded semaglutide or tirzepatide the same as Wegovy or Zepbound?
No. Compounded versions are legal 503A preparations containing the same active ingredient, but they are not FDA-approved products and have not gone through the same manufacturing review. The clinical trial results cited by platforms like HealthRX come from branded-drug studies, not from compounded formulations dispensed by telehealth services.
Which of these platforms is worth it if you have insurance?
Ro Body and PlushCare are the strongest options here. Ro has a dedicated prior-authorization team specifically for branded GLP-1s, and PlushCare accepts insurance for branded medications through a primary-care model. Hims & Hers also accepts insurance post-settlement, with some patients reaching $0 to $25 monthly through manufacturer savings cards.
Why did Hims & Hers stop offering compounded semaglutide?
The March 2026 Novo Nordisk settlement changed the legal space for several large telehealth platforms that had been dispensing compounded semaglutide. Hims & Hers shifted to branded medications after that point. Wegovy, oral semaglutide, and Zepbound replaced their compounded offerings, at noticeably higher base prices for uninsured patients.
What should you ask a telehealth provider before your first prescription?
Three things worth asking directly: which specific pharmacy fills your medication, whether batch testing results are available to patients, and what happens if you need a dose adjustment mid-month. Providers like FormBlends publish HPLC purity data and sterility results. Most do not. How a platform answers those questions tells you a lot about how it operates.
Sources
- FDA warning letters to compounding and telehealth firms, early 2026 (FDA.gov press releases)
- SURMOUNT-1 trial results (tirzepatide), published in the New England Journal of Medicine, 2022
- STEP 1 trial results (semaglutide), published in the New England Journal of Medicine, 2021
- Novo Nordisk settlement announcement, March 2026 (company press release and trade coverage)
- LillyDirect orforglipron pricing, April 2026 (Eli Lilly investor and product communications)
- LegitScript certification directory (LegitScript.com)
